

Form PTO-1449 (Modified)  
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTORNEY DOCKET NO.:  
10062-1APPLICATION NO.  
09/227,749

## INFORMATION DISCLOSURE CITATION

(Form PTO-1449 Modified 5/95)  
(Use several sheets if necessary)APPLICANT:  
Brian J. Balin, et alFILING DATE:  
January 8, 1999GROUP ART UNIT:  
1623

## U.S. PATENT DOCUMENTS

EX. INIT	DOCU- MENT	DOCUMENT NUMBER	DATE	NAME
6		5,034,506	July 1991	Summerton et al.

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

6	•	Abrams et al., 1991, J. Immunol. 146:1455-1462
6	•	Abrams et al., 1993, Cancer Res. 53:5501-5506
6	•	Abrams et al., 1991, J. Invest. Dermatol. 96:31-37
6	•	Alonso et al., 1996, Nature Med. 2:783-787
6	•	Andersen et al., 1995, Neurology 45:1441-1445
6	•	Appelt et al., 1996, J. Histochem. Cytochem. 44:1421-1427
6	•	Barbas, 1995, Nature Medicine 1:837-839
6	•	Bird et al., 1988, Science 242:423-426
6	•	Blacker et al., 1997, Neurol. 48:139-147
6	•	Bolton et al., 1993, Ann. Neurol. 33:94-100
6	•	Branigan et al., 1996, Arthritis Rheumat. 39:1740-1746
6	•	Breitner et al., 1994, Neurology 44:227-232
6	•	Breteler et al., 1992, Epidemiol. Rev. 14:59-82
6	•	Bretschneider et al., 1981, Am. J. Clin. Path. 76:450-453
6	•	Burton and Barbas, 1994, Adv. Immunol. 57:191-280
6	✱	Campbell et al., 1995, J. Infect. Dis. 172:585-588

EXAMINER

6 P. K. P. K.

DATE CONSIDERED

6-7-00

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)  
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTORNEY DOCKET NO.:  
10062-1APPLICATION NO.  
09/227,749

## INFORMATION DISCLOSURE CITATION

(Form PTO-1449 Modified 5/95)  
(Use several sheets if necessary)APPLICANT:  
Brian J. Balin, et al.FILING DATE:  
January 8, 1999GROUP ART UNIT:  
1623

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

6	•	Capron, 1996, Nature Med. 2:856-857
5	•	Chakravarthy et al., 1995, Curr. Eye Res. 14:285-294
5	•	Clark et al., 1993, Arch. Neurol. 50:1164-1172
5	•	Connors et al., 1995, Stem Cells, 13:501-511
6	•	Cook et al., 1996, Proc. Natl. Acad. Sci. USA 93:9223-9228
6	•	Corder et al., 1993, Science 261:921-923
5	•	de Kruif et al., 1995, J. Mol. Biol. 248:97-105
5	•	Evans et al., 1989, J. Amer. Med. Assn. 262:2551-2556
5	•	Friedland et al., Arch. Neurol. 47:177-178
5	•	Gautrin et al., 1989, Can. J. Neurol. Sci. 16:375-387
5	•	Gaydos et al., 1992, J. Clin. Microbiol. 30:796-800
5	<del>•</del>	Gran et al., 1993, Scand. J. Rheumatol. 22:43-44
5	•	Grayston et al., 1993, J. Infec. Dis. 168:1231-1235
5	•	Grayston, 1992, Ann. Rev. Med. 43:317-323
5	•	Grayston et al., 1990, J. Infect. Dis. 161:618-625
5	•	Greenberg, 1990, Proc. Natl. Acad. Sci. USA 87:5827-5831
5	•	Gu et al., 1997, Thrombosis and Hematocyst 77(4):755-759
5	•	Hahn et al., 1991, J. Amer. Med. Assn. 266:225-230
5	•	Hatch, 1998, Science 282:754-759
5	•	Hixson et al., 1990, J. Lipid Res. 31:545-548

EXAMINER

L. K. K.

DATE CONSIDERED

6-20

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE (REV. 8-83) PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NO.: 10062-1	APPLICATION NO. 09/227,749
<b>INFORMATION DISCLOSURE CITATION</b> (Form PTO-1449 Modified 5/95) (Use several sheets if necessary)		APPLICANT: Brian J. Balin, et al.	
		FILING DATE: January 8, 1999	GROUP ART UNIT: 1623
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
6	*	Hofman et al., 1997, Lancet 349:151-153	
4	g	Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883	
7	o	Itzhaki et al., 1997, Lancet 349:241-244	
5	r	Johnson, 1994, J. Neurol. Sci. 124:3-14	
4	v	Keefover, 1996, Neurol. Clin. 14:337-351	
4	o	Kingsbury et al., 1995, Mol. Brain Res. 28:311-318	
7	<del>*</del>	Koskiniemi et al., 1996, Eur. Neurol. 36:160-163	
7	*	Kurosaka et al., 1998, J. Immunol. 161:6245-6249	
7	*	Lee et al., 1991, Science 251:675-679	
4	o	Lee et al., 1996, J. Neurosci. 16:7513-7525	
4	o	Leinonen, 1993, Eur. Heart J. 14:57-61	
4	o	Lemere et al., 1996, Nature Med. 2:1146-1150	
4	v	Li et al., 1998, Cell Biol. Int. 22:13-20	
6	v	Li et al., 1996, Arthritis Rheumat. 39:950-958	
7	o	Lippa et al., 1996, Neurol. 46:406-412	
4	o	Löbau et al., 1995, Mol. Microbiol. 18:391-399	
4	v	Lomax et al., 1990, Gene 86:209-216	
4	<del>*</del>	Malinverni, 1996, Curr. Opin. Infect. Dis. 9:150-156	
6	e	Mann et al., 1983, Acta Neurol. 60:24-28	
4	-	Marks et al., 1991, J. Mol. Biol. 222:581-597	
<b>EXAMINER</b> <i>W. Kish</i>			
<b>DATE CONSIDERED</b> <i>6/20</i>		<b>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in</b>	

Form PTO-1449 (Modified)  
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTORNEY DOCKET NO.:  
10062-1APPLICATION NO.  
09/227,749

## INFORMATION DISCLOSURE CITATION

(Form PTO-1449 Modified 5/95)  
(Use several sheets if necessary)APPLICANT:  
Brian J. Balin, et al.FILING DATE:  
January 8, 1999GROUP ART UNIT:  
1623

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

6	•	McKee et al., 1991, Ann. Neurol. 30:156-165
7	•	McKhann et al., 1984, Neurology 34:939-994
6	•	Mehta et al., 1998, J. Infect. Dis. 177:1326-1331
5	•	Melgosa et al., 1991, Infect. Immunol. 59:2195-2199
7	•	Melgosa et al., 1994, Infect. Immun. 62:880-886
6	•	Merrill et al., 1993, J. Immunol. 151:2132-2141
7	•	Mirra et al., 1991, Neurology 41:479-486
6	•	Miyashita et al., 1993, J. Med. Microbiol. 38:418-425
5	•	Montarras et al., 1994, In: The Polymerase Chain Reaction, Mullis et al., eds., Birkhäuser Press, Boston, MA, pp. 277-294
6	<del>•</del>	Muhlestein et al., 1996, J. Amer. Coll. Cardiol. 27:1555-1561
6	•	Nielsen et al., 1991, Science 254:1497-1500
7	•	Numazaki et al., 1995, J. Med. Microbiol. 42:191-195
6	•	Peterson et al., 1998, Infect. Immun. 66:3848-3855
6	•	Peterson et al., 1996, Infect. Immun. 64:3354-3359
7	•	Pogo et al., 1987, Brain 110:907-915
6	•	Poulakkainen et al., 1995, Microbiol. Immunol. 39:551-554
6	•	Renvoize et al., 1987, Age and Ageing 16:311-314
7	•	Rogers et al., 1993, Neurology 43:1609-1611
7	•	Roses, 1996, Ann. Rev. Med. 47:387-400
7	•	Schellenberg, 1995, Proc. Natl. Acad. Sci. USA 92:8552-8559
6	•	Sriram et al., 1998, Neurol. 50:571-572

EXAMINER

L. Kihle

DATE CONSIDERED

6-7-00

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)  
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTORNEY DOCKET NO.:  
10062-1APPLICATION NO.  
09/227,749

## INFORMATION DISCLOSURE CITATION

(Form PTO-1449 Modified 5/95)  
(Use several sheets if necessary)APPLICANT:  
Brian J. Balin, et al.FILING DATE:  
January 8, 1999GROUP ART UNIT:  
1623

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

4	•	Stagg, 1998, Mol. Med. Today 4:166-173
7	•	Strugnell et al., 1997, Immunol. Cell Biol. 75:364-369
7	•	Tuszynski et al., 1988, Blood, 72:109-115
7	•	Waldman, 1991, Science 252:1657-1662
7	•	Wang et al., 1996, Nature Med. 2:871-875
7	•	Whittum-Hudson et al., 1996, Nat. Med. 2:1116-1121
7	•	Wimmer et al., 1996, Stroke 27:2207-2210
7	•	Wisniewski et al., 1988, Ciba Fdn. Sympos. 135:224-238
7	•	Wong et al., 1992, J. Clinical Microbiol. 30:1625-1630
7	•	Wright et al., 1992, Critical Rev. in Immunol. 12(3,4):125-168
7	•	Yankner, 1996, Nature Med. 2:850-852
7	•	Zhang et al., 1997, J. Infect. Dis. 176:1035-1040

EXAMINER

4 Kish

DATE CONSIDERED

6-7-00

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(REV. 8-83) PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:  
10062-1 (210062.0001)

APPLICATION NO.:  
09/227,749


# **SUPPLEMENTAL INFORMATION DISCLOSURE CITATION**

(Form PTO-1449 Modified 5/95)  
(Use several sheets if necessary)

APPLICANT:  
Brian J. Balin et al.

FILING DATE:  
January 8, 1999

GROUP ART UNIT:  
1623



MAY 12 2000

## **U.S. PATENT DOCUMENTS**

EX. INIT	DOCU - MENT	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## **FOREIGN PATENT DOCUMENTS**

EX. INIT	DOCU - MENT	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## **OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

6		Jaruratanasirikul et al., March, 1996, "Distribution of Azithromycin Into Brain Tissue, Cerebrospinal Fluid, and Aqueous Humor of the Eye", <i>Antimicrobial Agents and Chemotherapy</i> , Vol 40, No. 3, p. 825-826.
6		Matthews, 1986, <i>Neuropathology and Applied Neurobiology</i> 12:111-116
6		Morbidity and Mortality Weekly Report, CDC, 1993 Sexually Transmitted Diseases Treatment Guidelines, 42:No. RR-14

EXAMINER E Peslev

DATE CONSIDERED

6-7-00

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.